Rhythm Pharmaceuticals, Inc.

RYTM · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.7%

Institutions114.8%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$189.76M	$130.13M	$77.43M	$23.64M	$3.15M	–	–	–	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$19.49M	$13.37M	$9.30M	$2.13M	$599000	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$192.02M	-$265.50M	-$184.36M	-$179.16M	-$170.06M	-$136.57M	-$146.00M	-$78.42M	-$32.41M
Operating income as a percentage of revenue.	-101.2%	-204.0%	-238.1%	-757.9%	-5391.9%	–	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$196.54M	-$260.60M	-$184.68M	-$181.12M	-$69.61M	-$134.00M	-$140.73M	-$74.06M	-$37.58M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.00	$-4.00	$-3.00	$-3.00	$-1.40	$-3.04	$-3.86	$-2.39	$-2.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.00	$-4.00	$-3.00	$-3.00	$-1.40	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$54.30M	$89.14M	$60.08M	$127.68M	$59.25M	$100.85M	$62.29M	$49.54M	$34.24M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$480.20M	$392.27M	$332.75M	$382.48M	$329.52M	–	$308.52M	$260.21M	$151.74M
All of the company's interest-bearing borrowings, short and long term combined.	$108.20M	$109.81M	–	–	–	–	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$210.17M	$227.72M	$162.99M	$118.22M	$45.37M	–	$27.50M	$13.95M	$6.95M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$139.07M	$21.73M	$169.76M	$264.26M	$284.15M	–	$281.02M	$246.26M	$144.79M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$115.67M	-$113.88M	-$136.16M	-$173.43M	-$146.00M	-$121.98M	-$122.75M	-$62.06M	-$29.46M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$953000	–	$47000	$281000	$434000	$214000	$3.38M	$722000	$133000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$116.63M	–	-$136.20M	-$173.71M	-$146.44M	-$122.19M	-$126.14M	-$62.78M	-$29.59M

	You	Peer avg
P/E	–	2.6
Revenue Growth	+46.9%	+45.4%
ROE	-117.0%	-62.7%

Rhythm Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison